Week in review: Neffy repeat dose study data, fostering healthy eating habits
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
Image credit: Contemporary Pediatrics
Thank you for visiting the Contemporary Pediatrics® website. Take a look at some of our top stories from last week (Monday, February 19 to Friday, February 23, 2024), and click on each link to read and watch anything you may have missed.
1.) Neffy epinephrine nasal spray demonstrates positive data in repeat dosing study
ARS Pharma plans to submit data from the repeat dose study of neffy to the FDA early in the second quarter of 2024, as part of its response to the CRL issued by the federal agency for the previously submitted New Drug Application (NDA).
Click here for the full article.
2.) Fostering healthy eating habits
Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, shares her perspectives on the most recent issue of Contemporary Pediatrics.
Click here for her full commentary and highlights.
3.) Identifying arrhythmias in children using smartwatch technology
How effective can wearable technology with features designed for adults be for children when it comes to arrhythmias? Scott Ceresnak, MD, helps provide the answer in this Contemporary Pediatrics interview.
Click here to watch the full video interview.
4.) FDA grants Priority Review to pitolisant for pediatric narcolepsy patients
A Prescription Drug User Fee Act (PDUFA) target action date has been set for June 21, 2024, following a supplemental New Drug Application (sNDA) submission by Harmony Biosciences.
5.) Duchenne muscular dystrophy treatment receives Rare Pediatric Disease designation
The FDA has granted a Rare Pediatric Disease Designation to Avidity Biosciences' AOC 1044, an investigational therapy to treat Duchenne muscular dystrophy (DMD) in patients with mutations amenable to exon 44 skipping (DMD44).
Fast Track Designation and Orphan Designation was previously granted to AOC 1044.
Dupilumab safe, effective for up to 1 year for atopic dermatitis in infants, preschool children
May 3rd 2024According to new study data presented at the 2024 Pediatric Academic Societies Meeting, dupilumab (dupixent; Sanofi and Regeneron) demonstrated positive safety and efficacy results for up to 1 year in infants and preschool-age children with atopic dermatitis.
